3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
CNS
1
Conditions
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Recurrence
1
Neuroblastoma
1
Neoplasms
1
Melanoma
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, B-Cell
1
Leukemia
1
Glioma
1
Ependymoma
1
Interventions
Topotecan
2
Psychiatric Rehabilitation
2
trioctyl phosphine oxide
1
romidepsin
1
ixabepilone
1
entinostat
1
carboxyamido-triazole
1
bempegaldesleukin
1
Vorinostat
1
Thalidomide
1
Paclitaxel
1
Nivolumab
1
N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L-ornithine
1
Megestrol Acetate
1
Isotretinoin
1
Gelclair
1
Fentanyl
1
Drug Therapy
1
Docetaxel
1
Dexamethasone
1
Cyproheptadine
1
Calcium Dobesilate
1
Busulfan
1
90Y-octreotide, DOTA-Tyr(3)-
1
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Medulloblastoma
×
bempegaldesleukin
×
Other hematologic neoplasm
×
Clear all
NCT04730349
2023-03-24
PIVOT IO 020
Bristol-Myers Squibb
Phase 1/2
Terminated
15 enrolled
14 charts